Introduction:
The prevalence of hepatitis C virus (HCV) in Russia is
nearly three-fourths of the HCV prevalence in the United States. Russia also
has a large diagnosed population and relatively low treatment rates. The
expected rise in government healthcare spending will expand the availability of
more-expensive and more-efficacious therapies to HCV patients and will be one
of the major factors driving market growth.
Questions Answered in This Report:
*
Approximately 2% of Russia’s population is infected with HCV,
but only a small proportion of patients receive treatment.
How will the HCV
diagnosis and drug-treatment rates change over 2008-2013? What factors will
influence the changes in diagnosis and drug-treatment rates?
*
The price of a treatment regimen is the major factor
influencing Russian clinicians’ choice of therapy for HCV.
How do clinicians
perceive pegylated interferons compared with conventional interferons? How do
clinicians perceive generics compared with branded products?
*
The majority of HCV therapy sales in Russia in 2008 occurred
within the government reimbursement segment of the market.
Where are the key
opportunities for growth in the HCV antiviral market? Which agents will drive
market growth over the forecast period? Which drugs will dominate the market in
2013?Scope:
Market covered: Russia
Primary research: 90 clinicians surveyed in Moscow,
Novosibirsk, and St. Petersburg. Separate in-depth interviews with 10 Russian
medical and regulatory experts.
Epidemiology: Prevalence of HCV in Russia over a
ten-year period (2008-2018) based on age and gender, major city, and stage of
disease (i.e., chronic versus acute).
Market forecast features: Our analysis evaluates rates
of chronic HCV diagnosis and rates of drug treatment with HCV therapies. We
include a detailed forecast for two HCV drug classes and leading products from
2008 through 2018, using a combination of historical trend analysis and an
epidemiology-based, bottom-up market model.